XML 63 R37.htm IDEA: XBRL DOCUMENT v3.6.0.2
Organization, Basis of Presentation and Liquidity, Principles of Consolidation and Liquidity (Details) - USD ($)
$ in Thousands
1 Months Ended
Feb. 15, 2017
Feb. 28, 2017
Dec. 31, 2016
Dec. 31, 2015
Dec. 31, 2014
Dec. 31, 2013
Noncontrolling Interest [Line Items]            
Accumulated deficit     $ (196,321) $ (229,893)    
Working capital     17,000      
Shareholders' equity     130,508 $ 76,447 $ 62,723 $ 42,261
Cash, cash equivalents and available for sale securities     $ 12,500      
Subsequent Event [Member] | Common Stock [Member]            
Noncontrolling Interest [Line Items]            
Proceeds from issuance initial public offering $ 18,700 $ 18,700        
Cell Cure Neurosciences, Ltd. [Member] | Israel [Member]            
Noncontrolling Interest [Line Items]            
BioTime Ownership [1]     62.50%      
ES Cell International Pte. Ltd. [Member] | Singapore [Member]            
Noncontrolling Interest [Line Items]            
BioTime Ownership     100.00%      
LifeMap Sciences, Inc. [Member] | USA [Member]            
Noncontrolling Interest [Line Items]            
BioTime Ownership     77.90%      
LifeMap Sciences, Ltd. [Member] | Israel [Member]            
Noncontrolling Interest [Line Items]            
BioTime Ownership [2]     0.00%      
LifeMap Solutions, Inc [Member] | USA [Member]            
Noncontrolling Interest [Line Items]            
BioTime Ownership [2]     0.00%      
OncoCyte Corporation [Member] | USA [Member]            
Noncontrolling Interest [Line Items]            
BioTime Ownership [3]     51.10%      
OrthoCyte Corporation [Member] | USA [Member]            
Noncontrolling Interest [Line Items]            
BioTime Ownership     100.00%      
ReCyte Therapeutics, Inc. [Member] | USA [Member]            
Noncontrolling Interest [Line Items]            
BioTime Ownership     94.80%      
[1] Includes shares owned by BioTime and ES Cell International Pte. Ltd.
[2] LifeMap Sciences, Ltd. and LifeMap Solutions, Inc. are wholly-owned subsidiaries of LifeMap Sciences, Inc.
[3] See Note 16. Beginning February 17, 2017, BioTime deconsolidated OncoCyte and OncoCyte is no longer a subsidiary of BioTime as of that date.